PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, including rare diseases and oncology. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of SMA in adults and children two months and older in Brazil.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
PTC Therapeutics, Inc news
04.05.2022
The loss of PTC Therapeutics under GAAP for the 3 months of 2022 was $126.726 million, down 1.5% from $128.642 million in the previous year. Revenue increased 26.1% to $148.735 million compared to $117.942 million a year earlier.
Source: 
ir.ptcbio.com
ir.ptcbio.com
General information
| Company name | PTC Therapeutics, Inc |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 100 Corporate Court South Plainfield, NJ 07080 United States |
| Mailing address | 100 Corporate Court South Plainfield, NJ 07080 United States |
| Website | ir.ptcbio.com |
English (US) 